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Abstract: The prevalence of Candida parapsilosis, an opportunistic human patho-
genic fungal species, is increasing at an alarming rate in the hospital environment. 
Patients at risk for C. parapsilosis infection include those with immunosuppression, 
such as individuals with cancer, AIDS, and low birth weight premature neonates as 
well as patients that had undergone abdominal surgery. Neonatal candidiasis caused 
by C. parapsilosis has been widely reported across the globe. Various reports have 
shown that, compared to other Candida species, certain C. parapsilosis clinical iso-
lates were less susceptible to antifungals such as amphotericin B, fluconazole, and 
caspofungin. In addition, some studies have even reported multi-echinocandin or 
multi-azole resistant strains of C. parapsilosis. C. parapsilosis has several virulence 
factors that contribute to its capacity for host invasion and among these factors extracellular lipases 
have a major role in pathogenesis. In this review we have collected all the recent relevant studies that 
confirm the involvement of secreted lipases in C. parapsilosis pathogenesis, using both in vitro and in 
vivo models of infection. Of particular note, an available lipase deficient C. parapsilosis strain has 
been utilized to demonstrate that the lack of secreted lipases decreased virulence, reduced tissue dam-
age, and was less able to survive within phagocytes or mice compared to the wild type. Since fungal 
secreted lipases have different characteristics than lipolytic enzymes present in humans, C. parapsilo-
sis extracellular lipases may be potential targets for the development of novel antifungal drugs. 
Keywords: Candida parapsilosis, extracellular lipase, pathogenicity, macrophages, dendritic cells, reconstituted human tissue, 
in vivo models. 
INTRODUCTION 
Despite of the wide range of available antifungal medi-
cines, nosocomial fungal infections remain a major concern 
[1-3]. Recent studies detail that invasive candidiasis is the 
leading cause of mycosis-associated mortality worldwide [4-
7]. Although the opportunistic pathogen Candida albicans is 
the most common species found in the hospital environment, 
numerous non-albicans Candida (NAC) species have been 
isolated from patients as a source of primary infection [8, 9]. 
More significantly, the frequency of invasive disease due to 
NAC species such as C. parapsilosis is rising alarmingly 
[10, 11]. One reason for the increased incidence of C. parap-
silosis infections is that the species displays notable resis-
tance to antifungals drugs [11, 12]. Several studies have re-
ported C. parapsilosis clinical isolates with reduced suscep-
tibility to different types of antifungals such as Amphotericin 
B, fluconazole, anidulafungin, and caspofungin when com-
pared to other Candida species [13-15, 14c]. In addition, 
multi-echinocandin and multi-azole-resistant clinical strains 
have been also isolated from patients [14b]. Horizontal 
transmission is also a characteristic of this species [16]. 
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Taken together, these factors suggest that, the number of 
resistant C. parapsilosis strains might further increase in the 
future. 
Since the ‘90s, reports have frequently associated C. 
parapsilosis with nosocomial infections among children and 
newborns [17-21]. Several recent studies have further re-
ported C. parapsilosis to be the predominant species causing 
neonatal infections at intensive care units (ICU), threatening 
especially low birth weight infants, with significant neonatal 
mortality [7, 22-24]. Additionally, diverse adult patients with 
diminished immunity are also at risk [25-28]. Further risk 
factors include the use of lipid rich parenteral nutrition and 
prolonged use of implanted devices, as C. parapsilosis read-
ily forms and maintains stable biofilms on the surfaces of 
commonly used medical equipments [29].  
Microbial secreted hydrolytic enzymes are known to con-
tribute to the process of fungal pathogenesis. Such enzymes 
include extracellular proteinases, phospholipases and lipases 
[30-32]. The role of fungal secreted lipases is pleiotrop as 
they modulate the immune response in various ways [33]. 
Both cellular and humoral host responses are affected and 
they also contribute to host tissue damage, allowing fungal 
cells to invade the host [33-35]. Based on a large number of 
recent studies, C. parapsilosis is considered an emerging 
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pathogen, and since its clinical relevance is clear, attention 
should be increased towards this NAC species. 
A number of reports and previous reviews have already 
demonstrated the role of C. parapsilosis in nosocomial infec-
tions [23, 24, 29, 36]. In this review, we aim to provide a 
description of a critically important effector protein of C. 
parapsilosis that has been proven to promote invasion, in-
cluding altering host immune responses to the benefit of the 
fungus. We will detail how fungal secreted lipases influence 
the virulence of C. parapsilosis and thus provide evidence 
that fungal lipases should be considered a target for develop-
ing antifungals in the future. 
FUNCTION OF FUNGAL SECRETED LIPASES 
Fungal secreted lipases can have a variety of functions, 
due to their ability to catalyze a wide range of reactions such 
as the hydrolysis or synthesis of triacylglycerols [37]. Many 
microbial extracellular lipases are used for industrial pur-
poses as biocatalysts and Candida species are frequently 
used to produce hydrolytic enzymes for industrial use [38, 
39]. For example, C. antartica and C. rugosa secreted lipases 
are the most frequently used biocatalysts that are involved in 
detergent industry, biosensor modulation, and even biocata-
lytic resolution of pharmaceuticals such as antibiotics, viru-
cids, probiotics and non-steroid anti-inflammatory drugs 
(NSAIDs) [38, 40, 41]. Thus, fungal secreted lipases are 
considered beneficial for biotechnological applications.  
However, the role of secreted lipase as a potential viru-
lence factor on the level of a pathogenic microorganism is 
also quite evident [31, 42]. In addition to the key roles of 
lipases in nutrient acquisition, they might also augment ad-
hesion to host tissues, lyse competitive microflora, and 
modulate host inflammatory reactions, which can also result 
in further tissue damage [29, 43]. Therefore, fungal secreted 
lipases contribute to host invasion in diverse ways.  
C. albicans is known to have 10 lipase encoding genes, 
one (LIP1) characterized by Fu et al. [44] and nine (LIP2-
LIP10) by Hube et al. [31]. Further examinations of C. albi-
cans lipases revealed that individual genes are regulated dif-
ferently during an infection and gene expression of each 
ORF was mainly dependent upon the stage of infection [45]. 
Interestingly, the different genes had variable contributions 
to virulence. The role of LIP5 and LIP8 in C. albicans viru-
lence was highlighted as their expression levels remained the 
highest when examining isolates recovered from systemi-
cally infected mice or from human oral specimens [45]. Fur-
thermore, the generation of a C. albicans strain lacking LIP8 
led to experiments demonstrating that this null mutant was 
less virulent in vivo compared to wild-type [46]. These re-
ports suggest that differential regulation of lipase gene ex-
pression has helped C. albicans to adapt to the human host. 
Lipid acquisition from the host has already been reported 
in Candida species. Both C. albicans and C. parapsilosis 
assimilate exogenic arachidonic acid in order to produce 
human prostaglandin-like molecules (PGE2 and PGD2) [47, 
48]. Fungal prostaglandins were shown to modulate host 
immune responses via a variety of mechanisms to promote 
host colonization [49]. Furthermore, C. albicans morpho-
genesis is also influenced by PGE2 [49]. Secreted lipases 
contribute to the release of lipid intermediers during host 
invasion, and therefore also indirectly influence fungal viru-
lence. 
CpFIT2 (Fat storage-Inducing Transmembrane protein 2) 
is involved in fungal lipid droplet (LD) formation. According 
to Nguyen et al. FIT2 has a role in triacil glycerol (TAG) 
synthesis and may be required for the balance between lipid 
species via LD formation. It is notable, that defect of CpFIT2 
leads to reduced LD formation, altered fatty acid composi-
tion growth disabilities and increased susceptibility to oxida-
tive stressor. Furthermore, FIT2 deletion also resulted in 
reduced virulence in murine infection models, further sup-
porting the role of fungal lipids in pathogenicity [50]. 
C. parapsilosis is considered to be less pathogenic than 
C. albicans, although its relevance is increasing in the hospi-
tal environment and it even outranks C. albicans in some 
health care centers as a cause of invasive candidiasis [29]. C. 
parapsilosis has only two indentified secreted lipase coding 
genes [29]. The presence of only two secreted lipase encod-
ing genes facilitated the construction of a secreted lipase-null 
strain, a double knock-out strain, which has proven to be a 
valuable tool for studying the role of extracellular lipases 
during host-pathogen interactions.  
IDENTIFICATION OF C. PARAPSILOSIS SECRETED 
LIPASES 
Fu et al. published the first report that suggested the 
presence of secreted lipases in C. parapsilosis in 1997 [44]. 
Five years later, Neugnot et al. identified two lipase encod-
ing ORFs in this species [51]. Amino acid sequence com-
parison revealed that these identified proteins might belong 
to the same Candida lipase gene family that was described 
by Hube et al. in C. albicans, thus they might be also in-
volved in fungal pathogenesis. The newly found C. parapsi-
losis lipase encoding ORFs showed the highest homology 
with C. albicans LIP1. Accordingly, the ORFs were named 
CpLIP1 and CpLIP2. Expression analysis of the two C. 
parapsilosis lipase genes in S. cerevisiae and later in P. pas-
toris revealed that only CpLIP2 coded for a functional pro-
tein [51, 52]. C. parapsilosis LIP1 and LIP2 are encoded by 
two neighboring ORF regions with an approximate size of 
1300 bp for each [51]. Both lipases consist of a deduced 465 
amino acid sequence with two CUG codons present in 
CpLIP1 but none in CpLIP2. As C. parapsilosis is a member 
of the CUG-clade (serine instead of leucine translation), this 
might be an explanation why the enzyme encoded by 
CpLIP1 is not functional when expressed in S. cerevisiae 
[51]. CpLIP2 was further described with a molecular mass of 
60 kDa and was shown to contain the Gly-X-Ser-X-Gly con-
sensus motif that is highly conserved and commonly found 
in the serine catalytic core of lipolytic enzymes [51]. The 
lipase from C. parapsilosis catalyses the alcoholysis of vari-
ous esters. According to Briand el al., this lipase showed the 
highest activity when unsaturated fatty acids with a cis-delta 
9 double bond or the ester bond of long-chain fatty acids 
were present in the medium [53]. During the investigation of 
biochemical properties, it was also shown that the catalytic 
activity was also dependent upon the temperature of the reac-
tant medium [53]. 
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After whole genome sequencing, two additional LIP-like 
genes were suggested that may be present in the C. parapsi-
losis genome, however, these remained uninvestigated [29]. 
Expression studies of CpLIP genes using other yeasts highly 
contributed to our knowledge on C. parapsilosis lipase secre-
tion, but did not address their role in virulence. Although 
there were advances in C. parapsilosis genetic manipulation 
[12, 54] , it was not until 2007 that an innovative method for 
targeted gene deletion became available, and LIP1 - LIP2 
were one of the first genes to be deleted from the diploid 
genome of C. parapsilosis, using a dominant selection 
marker carrier flipper cassette [34]. The available null mu-
tant strain (Cp ΔΔlip1-ΔΔlip2) provided us a novel tool for 
studying C. parapsilosis lipases and facilitated numerous 
subsequent virulence related investigations. Early studies 
demonstrated the role of CpLIP1-LIP2 in viability in lipid 
rich environment, biofilm formation, and adherence to host 
surfaces as well as to immune response modulation [34]. 
IN VITRO HOST EFFECTOR CELL - C. PARAPSILO-
SIS INTERACTIONS 
Using the previously mentioned lipase deficient strain, 
several studies confirmed the role of C. parapsilosis lipases 
in virulence (Fig. 1) [33, 34, 55, 56]. Initial studies focused 
on the interactions of C. parapsilosis with murine macro-
phages. The lipase deficient Cp ΔΔlip1-ΔΔlip2 yeast cells 
induced higher phagocytic and killing efficiency by murine 
macrophages in vitro when compared to the lipase secreting 
wild type cells (Fig. 2) [34]. Subsequent studies with human 
peripheral blood mononuclear cell – derived macrophages 
(PBMC-DMs) [33] and dendritic cells (DCs) [55] reported 
similar outcomes. Overall, the Cp ΔΔlip1-ΔΔlip2 strain ap-
peared to be less virulent, as both types of human primary 
cells were able to kill mutant cells in a higher ratio compared 
to wild type cells. Intracellular survival of C. parapsilosis 
cells following phagocytosis has been recently reported [35]. 
In contrast with DCs, no difference was detected in the 
phagocytic efficiency of fungal cells by PBMC-DMs, al-
though early phago-lysosome fusion was detected in both 
cases [33, 55]. These results led to the conclusion that fungal 
lipase secretion delays phagosome maturation, thus is con-
sidered to be one of the factors that contribute to fungal sur-
vival inside host cells.  
In addition to their roles as professional phagocytes and 
professional antigen presenting cells, PBMC-DMs and DCs 
release certain types of effector molecules or cytokines to 
modulate immune responses. These cytokines include inter-
leukin – 1 (IL-1), interleukin – 6 (IL-6) and tumor necrosis 
factor alpha (TNFα) as major inducers of inflammatory reac-
tions; IL-8 as a neutrophil chemotactic factor and other 
chemokines to recruit leukocytes to the infection site [57, 
58]. Cyclooxygenase 2 (COX-2) is essential for the synthesis 
of the biologically active inflammation inducer prostaglandin 
E2 [48]. Toth A. et al. and Nagy and Filkor et al. reported 
that both DCs and PBMC-DMs released IL-1, IL-6 and 
TNFα pro-inflammatory cytokines at a markedly increased 
level in the presence Cp ΔΔlip1-ΔΔlip2 cells compared to 
that occurring in the presence of wild type yeast cells and an 
elevated level of IL-8 was detected after DCs were chal-
lenged with Cp ΔΔlip1-ΔΔlip2 compared to wild type cells 
[55]. Similarly, higher levels of IL-8 and COX-2 expression 
were observed when PBMC-DMs were treated with the li-
pase deficient mutant in comparison with wild type strain. 
Interestingly, the anti-inflammatory response of PBMC-DM 
was also modulated, as an elevated IL-10 level was found 
after exposure to Cp ΔΔlip1-ΔΔlip2 compared to that occur-
ring after challenge with wild type yeast [33, 55].  
In summary, the lack of the secreted lipase led to a 
stronger inflammatory response, shown by the increase in the 
pro-inflammatory cytokine and chemokine expression levels, 
as well as by more efficient killing and phagocytosis of Cp 
ΔΔlip1-ΔΔlip2 cells by professional phagocytes. These re-
ports suggest that C. parapsilosis secreted lipases suppress 
both the cellular and humoral immune responses and thus 
have a protective role against host responses.  
TISSUE MODELS FOR C. PARAPSILOSIS EX-
TRACELLULAR LIPASES 
In the macrophage - C. parapsilosis model, host cell 
damage by fungal cells was not affected by the presence of 
secreted lipases [33]. However, this did not mean that the 
extracellular lipases could not impact more complex tissues 
and the utilization of reconstituted human tissue (RHT) 
models allowed for the first assessment of C. parapsilosis 
lipase on virulence. Although RHTs had been used to model 
cutaneous, oral and vaginal C. albicans disease [59-61], they 
had not been applied to the study of C. parapsilosis to assess 
the histopathological effect of microbial secreted hydrolytic 
enzymes such as fungal extracellular lipases [34, 62]. In lipid 
rich environment fungi use secreted lipases to digest lipids in 
order to supply basic nutrient needs [29]. Oral epithelial 
RHT challenged with C. parapsilosis wild type cells develop 
severe histopathological changes such as atrophy, edema, 
and clefting in all tissue layers, along with higher rates of 
apoptosis [34]. In contrast, Cp ΔΔlip1-ΔΔlip2 induced mini-
mal injury, as the infected tissue was histologically similar to 
the uninfected control and their ability to attach to the epithe-
lial surface was significantly decreased compared to wild 
type [34]. Using lactate-dehydrogenase (LDH) release as a 
determinant of RHT damage, the wild type C. parapsilosis 
yeasts caused significantly reduced cellular damage com-
pared to the lipase mutant cells [34]. Additionally, inhibition 
of lipase by Ebelactone B, quinine or acetylysalicylic acid 
abrogated RHT infection and damage caused by C. parapsi-
losis [62, 63]. These findings further supported the involve-
ment of C. parapsilosis extracellular lipases in tissue adhe-
sion and destructive disease. 
IN VIVO INFECTION MODELS TO STUDY C. 
PARAPSILOSIS LIPASE FUNCTION 
In order to study systemic immune responses and in-
flammation triggered by pathogenic fungi, numerous in vivo 
infection models are in use. Even though, newly emerging 
non-conventional in vivo models of infection are becoming 
popular, mammalian models are still of central importance 
[64, 65]. Although Galleria mellonella has been described as 
a model to study Candida species virulence, including C. 
parapsilosis [65, 66], mice remain the most suitable and 
widely accepted model of candidiasis; however, occasion-
ally, certain types of rats are also used. A common method to 
investigate non-lethal disease is to perform fungal burden
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Fig. (1). The role of fungal extracellular lipases in host invasion. The image represents the putative role of C. parapsilosis secreted lipases 
during pathogenesis. Fungal secreted lipases directly contribute to nutrient acquisition and host cell lysis. Microbial extracellular lipases may 
also be responsible for directly lysing competitive microflora. Besides their direct roles in virulence they might influence fungal adhesion 
properties; delay inflammatory processes due to the release of chemical mediators from damaged cells; and contribute to intracellular survival 
as a result of phago-lysosome fusion inhibition. 
 
Fig. (2). Phagocytosis of C. parapsilosis cells. Representative image shows the phagocytosis of C. parapsilosis wild type (A) and lipase null 
mutant cells (B) by human peripheral blood mononuclear cell – derived macrophages. Acridine orange and crystal violet were used for stain-
ing. Orange / red fluorescence indicates cell death, while live cells emit green fluorescence. Scale bar: 20µm. 
assessments of organs by means of colony forming unit 
(CFU) counting of plated organ homogenates. Using a in-
traperitoneal murine infection model, it has been demon-
strated that Cp ΔΔlip1-ΔΔlip2 cells were able to accumulate 
less in the kidney, liver and spleen of BALB/c mices 2 days 
post infection [34], but these mutant cells were eradicated 
within 4 days after the infection, which was significantly 
faster than clearance of wild type yeast [34]. As C. parapsi-
losis is one of the leading species associated with neonatal 
invasive infections, efforts have been applied to developing a 
suitable model to mimic newborn-related candidiasis [67-
69]. Using newborn Sprague–Dawley rats, Trofa et al. 
demonstrated that premature neonates were highly 
susceptible to candidal infections. Moreover, this rat pup 
candidal infections. Moreover, this rat pup model proved to 
be effective for detecting the effects of the presence or ab-
sence of extracellular lipases. In their experiments, they in-
fected newborn rats intravenously (IV), intragastrically (IG) 
and intraperitoneally (IP) either with the lipase secretion 
deficient strain of C. parapsilosis, a LIP8 deficient strain of 
C. albicans or their corresponding wild type strains. Notably, 
both CpΔΔlip1-ΔΔlip2 and CaΔΔlip8 displayed significantly 
lower virulence compared to wild type strains as indicated by 
reduced organ fungal burdens. These findings of in vivo 
studies further demonstrate the crucial role of fungal secreted 
lipases in C. parapsilosis pathogenicity. 
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CONCLUSIONS 
C. parapsilosis is an opportunistic human pathogenic 
species that is commonly associated with nosocomial fungal 
diseases, and this species continues to emerge in incidence 
and importance. Fundamental molecular investigations cou-
pled with in vitro and in vivo studies have made major strides 
in elucidating several of the factors that facilitate the patho-
genesis of C. parapsilosis. One of the best described viru-
lence factors is the secreted lipases of C. parapsilosis, and 
the availability of lipase deletion strains has facilitated the 
study of C. parapsilosis virulence properties. There are now 
numerous reports that clearly detail the importance of C. 
parapsilosis extracellular lipases in pathogenesis as their 
presence alters cellular and humoral immune responses, de-
lays inflammatory reactions, contributes to host tissue adhe-
sion and promotes intracellular survival. In this review, we 
described the key role of secreted lipases in C. parapsilosis 
virulence, as another potential factor of this species that can 
be targeted by a novel class of antifungals of future medi-
cine. 
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DC = dendritic cell;  
RHT = reconstituted human tissue. 
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